Phillip Md Et Al Frost Acquires 44,500 Shares of Opko Health Inc. (OPK) Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 44,500 shares of the stock in a transaction on Wednesday, April 5th. The shares were bought at an average price of $7.69 per share, for a total transaction of $342,205.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $23,600,233.19. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, May 3rd, Phillip Md Et Al Frost purchased 11,000 shares of Opko Health stock. The stock was acquired at an average price of $7.53 per share, for a total transaction of $82,830.00.
  • On Tuesday, May 2nd, Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock. The shares were purchased at an average price of $7.58 per share, for a total transaction of $113,700.00.
  • On Monday, May 1st, Phillip Md Et Al Frost acquired 4,700 shares of Opko Health stock. The shares were purchased at an average price of $7.68 per share, for a total transaction of $36,096.00.
  • On Friday, April 28th, Phillip Md Et Al Frost bought 9,000 shares of Opko Health stock. The shares were bought at an average cost of $7.78 per share, for a total transaction of $70,020.00.
  • On Thursday, April 27th, Phillip Md Et Al Frost bought 22,500 shares of Opko Health stock. The shares were bought at an average cost of $7.81 per share, for a total transaction of $175,725.00.
  • On Wednesday, April 26th, Phillip Md Et Al Frost acquired 5,000 shares of Opko Health stock. The stock was acquired at an average cost of $7.84 per share, for a total transaction of $39,200.00.
  • On Friday, April 21st, Phillip Md Et Al Frost acquired 19,000 shares of Opko Health stock. The stock was acquired at an average cost of $7.48 per share, for a total transaction of $142,120.00.
  • On Wednesday, April 19th, Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock. The stock was acquired at an average cost of $7.49 per share, for a total transaction of $112,350.00.
  • On Tuesday, April 18th, Phillip Md Et Al Frost acquired 27,800 shares of Opko Health stock. The stock was acquired at an average cost of $7.26 per share, for a total transaction of $201,828.00.
  • On Monday, April 17th, Phillip Md Et Al Frost bought 13,600 shares of Opko Health stock. The stock was purchased at an average cost of $7.48 per share, with a total value of $101,728.00.

Shares of Opko Health Inc. (NASDAQ:OPK) opened at 7.55 on Friday. The stock’s market cap is $4.21 billion. Opko Health Inc. has a 12 month low of $7.11 and a 12 month high of $12.15. The company has a 50 day moving average price of $7.75 and a 200-day moving average price of $9.05.

Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, March 1st. The biotechnology company reported ($0.04) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.04). The business had revenue of $275.50 million for the quarter, compared to the consensus estimate of $310.82 million. Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%. Opko Health’s quarterly revenue was down .3% compared to the same quarter last year. On average, equities research analysts predict that Opko Health Inc. will post ($0.12) earnings per share for the current year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/opko-health-inc-opk-ceo-phillip-md-et-al-frost-purchases-44500-shares-of-stock-updated-updated/580517.html.

Several large investors have recently made changes to their positions in OPK. State Street Corp boosted its stake in shares of Opko Health by 3.0% in the fourth quarter. State Street Corp now owns 7,787,875 shares of the biotechnology company’s stock valued at $72,427,000 after buying an additional 226,132 shares during the last quarter. Norges Bank acquired a new stake in shares of Opko Health during the fourth quarter valued at $30,421,000. Dimensional Fund Advisors LP boosted its stake in shares of Opko Health by 2.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,589,903 shares of the biotechnology company’s stock valued at $14,811,000 after buying an additional 30,851 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Opko Health by 1.4% in the first quarter. Bank of Montreal Can now owns 1,044,576 shares of the biotechnology company’s stock valued at $8,357,000 after buying an additional 14,559 shares during the last quarter. Finally, RK Asset Management LLC boosted its stake in Opko Health by 0.4% in the first quarter. RK Asset Management LLC now owns 887,719 shares of the biotechnology company’s stock worth $7,102,000 after buying an additional 3,300 shares during the last quarter. 22.58% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have commented on OPK shares. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a report on Friday, March 3rd. Guggenheim assumed coverage on Opko Health in a report on Tuesday, March 14th. They issued a “buy” rating and a $25.00 target price for the company. Jefferies Group LLC reduced their target price on Opko Health from $10.00 to $8.00 and set a “hold” rating for the company in a report on Thursday, March 2nd. TheStreet lowered Opko Health from a “c-” rating to a “d+” rating in a report on Wednesday, February 1st. Finally, Standpoint Research reaffirmed a “buy” rating and issued a $14.00 target price on shares of Opko Health in a report on Sunday, March 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $15.64.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

5 Day Chart for NASDAQ:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with our FREE daily email newsletter.

 


Latest News

David Price and Red Sox to Meet Following Rehab Start
David Price and Red Sox to Meet Following Rehab Start
Lack of Offense Leading to Mediocrity for Boston Red Sox
Lack of Offense Leading to Mediocrity for Boston Red Sox
MLB and Facebook Announce Live Streaming for Games
MLB and Facebook Announce Live Streaming for Games
Can Anyway Stop the Houston Astros?
Can Anyway Stop the Houston Astros?
Kevin Pillar Turns from Defense to Offense
Kevin Pillar Turns from Defense to Offense
Chris Iannetta Hit in Face with 93mph Fastball
Chris Iannetta Hit in Face with 93mph Fastball


Leave a Reply

 
© 2006-2017 BBNS.